<DOC>
	<DOCNO>NCT01120210</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacodynamics ( study medication affect body ) pharmacokinetics ( drug absorb body , distribute within body remove body time ) intravenous administration JNJ-39588146 placebo 3-hour period patient heart failure . The high tolerated dose receive first 3 hour study administer patient additional 18 hour . There 3 dos give throughout administration period total 21 hour .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacodynamics Pharmacokinetics Intravenous Solution JNJ-39588146 Placebo Patients With Heart Failure</brief_title>
	<detailed_description>This study ass safety , tolerability , pharmacodynamics pharmacokinetics JNJ-39588146 placebo ( look like drug study active ingredient ) patient heart failure . This study conduct two part . Part 1 randomized ( study drug assign chance ) , double-blind ( neither physician patient know identity assign drug ) study 3 intravenous dos JNJ-39588146 placebo administer 1-hr interval ( total 3 hour ) 60 patient heart failure . Part 2 extended infusion JNJ-39588146 placebo administer high tolerate dose Part 1 additional 18 hour . The entire duration infusion could long 21 hour . There 1 4 chance get placebo . The participation period maximum 42 day , include screen visit , 2-day in-clinic period two follow-up visit . For part study , patient cardiac catheter place monitor heart function . Safety evaluation , include ECG ( electrocardiograph , measure electrical current heart ) , vital sign monitor side-effects perform . Additionally , blood urine sample collect evaluation . Part 1 : Patients receive intravenous ( IV ) solution three different dos JNJ-39588146 placebo administer 1 hour period total 3 hour . Part 2 : Patients participate sub study continue receive IV solution 18 hour total 21 hour administration .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients must diagnose heart failure Women must either postmenopausal surgically sterilize least 6 month ago Males must willing use acceptable birth control method 3 month last dose study medication . Patients must heartassist device heart transplant imminent need one Patients must ischemic attack within last 6 month heart attack within last month Patients must lung disease congenital heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiac Failure</keyword>
</DOC>